Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Nonmelanoma Skin Cancer Studies, and Cancer Immunotherapy and Biomarkers.
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
Discordance, accuracy and reproducibility study of pathologists’ diagnosis of melanoma and melanocytic tumors
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma
Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma
Baseline D-dimers as predictive marker of efficacy of cemiplimab treatment in cutaneous squamous cell carcinoma
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.
Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient care
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study.
Patients’ and dermatologists’ preferences in artificial intelligence–driven skin cancer diagnostics: A prospective multicentric survey study
S2k guideline basal cell carcinoma of the skin (update 2023)
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.
Using multiple real-world dermoscopic photographs of one lesion improves melanoma classification via deep learning
S2k‐Leitlinie Basalzellkarzinom der Haut (Aktualisierung 2023)
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - Update 2026
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up
The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.